Found: 3
Select item for more details and to access through your institution.
Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 6, p. 889, doi. 10.1111/bjh.13905
- By:
- Publication type:
- Article
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
- Published in:
- British Journal of Haematology, 2014, v. 164, n. 2, p. 233, doi. 10.1111/bjh.12622
- By:
- Publication type:
- Article
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.
- Published in:
- British Journal of Haematology, 2011, v. 154, n. 3, p. 325, doi. 10.1111/j.1365-2141.2011.08689.x
- By:
- Publication type:
- Article